Liquid biopsies for cancer
This article was originally published in Start Up
UK-based start-up Inivata Ltd. is using cell-free circulating tumor DNA (ctDNA), found in the bloodstream, to create a “liquid biopsy.” This has potential to make cancer diagnosis and testing less invasive for patients, enhance monitoring to track response to treatment of the disease, improve the treatment decision process for physicians, and support clinical trial design, potentially speeding new drugs to the market.
You may also be interested in...
Emerging Company Profile: Gadeta, a Dutch spin-out from University Medical Centre Utrecht, launched earlier this year to develop modified T-cell-based therapies that target metabolic dysregulation in solid and hematological malignancies.
PeptiMimesis is developing first-in-class transmembrane therapeutic peptides with potential in immuno-oncology, oncology and immune diseases. Its technology is based on research showing that targeting the transmembrane domain using a single peptide can block several of the processes involved in the development of cancer by disrupting dimerization of target receptors, impairing the formation of receptor complexes and indirectly blocking the subsequent signaling pathways
Redx Pharma PLC and its subsidiaries are focused on developing proprietary, small-molecule therapeutics to address areas of high unmet medical need principally in cancer, infection and autoimmune disease.